Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Dose-Dense Rituximab for ITP
Recruiting2 awardsPhase 1
Valhalla, New York
This trial is to study if a more frequent administration of Rituximab leads to less relapses in ITP patients and to measure the quality of life during and after treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.